Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.57 |
| ▸ | DRD4 | P21917 | 6/20 | 0.57 |
| ▸ | DRD3 | P35462 | 6/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14926393 | 1.00 | DRD2 (0.57) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL5987245 | 0.98 | DRD2 (0.59) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL15581288 | 0.94 | DRD2 (0.52) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL15581256 | 0.94 | DRD2 (0.52) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL12549929 | 0.94 | DRD2 (0.52) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL5985514 | 0.93 | DRD2 (0.59) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL9011652 | 0.91 | DRD2 (0.65) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL9011831 | 0.91 | DRD2 (0.65) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL3805304 | 0.89 | DRD2 (0.68) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL20234354 | 0.88 | DRD2 (0.50) | DRD2DRD4DRD3L3MBTL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20140221574-A1 | COPOLYMER, AND LIQUID CRYSTAL ALIGNMENT LAYER INCLUDING CURED PRODUCT THEREOF | DIC CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140154428-A1 | CINNAMIC ACID DERIVATIVE, POLYMER THEREOF, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING CURED PRODUCT THEREOF | DIC CORPORATION (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20140154428-A1 | CINNAMIC ACID DERIVATIVE, POLYMER THEREOF, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING CURED PRODUCT THEREOF | DIC CORPORATION (JP) | 2014-06-05 | — | — | US | disclosed |
| EP-2727947-A1 | COPOLYMER, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING HARDENED PRODUCT THEREOF | DIC Corporation (JP) | 2014-05-07 | — | — | EP | disclosed |
| EP-2727903-A1 | CINNAMIC ACID DERIVATIVE, POLYMER THEREOF, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING HARDENED PRODUCT OF SAID POLYMER | DIC Corporation (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20140121345-A1 | CINNAMIC ACID DERIVATIVE, POLYMER THEREOF, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING CURED PRODUCT THEREOF | DIC CORPORATION (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121345-A1 | CINNAMIC ACID DERIVATIVE, POLYMER THEREOF, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING CURED PRODUCT THEREOF | DIC CORPORATION (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20130116396-A1 | POLYMER FOR USE IN LIQUID CRYSTAL ALIGNMENT LAYER | DIC CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116396-A1 | POLYMER FOR USE IN LIQUID CRYSTAL ALIGNMENT LAYER | DIC CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| WO-2012165550-A1 | CINNAMIC ACID DERIVATIVE, POLYMER THEREOF, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING CURED ARTICLE THEREOF | DIC株式会社 (JP) | 2012-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | DRD2 3895/4885DRD4 3922/4885DRD3 3870/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | DRD2 4667/4885DRD4 4576/4885DRD3 4738/4885 |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | DRD2 2704/4885DRD4 3152/4885DRD3 3606/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | DRD2 4522/4885DRD4 4654/4885DRD3 4621/4885 |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | DRD2 4608/4885DRD4 4753/4885DRD3 4771/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | DRD2 3320/4885DRD4 3649/4885DRD3 3951/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | DRD2 4554/4885DRD4 4620/4885DRD3 4699/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | DRD2 4525/4885DRD4 4335/4885DRD3 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.